N-PORT filing recap · January 2022

What did ARK Genomic Revolution ETF buy in January 2022?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$4.08B

Positions

Estimated turnover

21.6%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

BNRBurning Rock Biotech Limited$13.25Mreported value+1.47M shares NRIXNurix Therapeutics, Inc.$7.54Mreported value+404.7K shares

Increased positions

EXASExact Sciences Corporation$355.93Mreported value+539.7K shares+13.1%NTLAIntellia Therapeutics, Inc.$177.07Mreported value+158.8K shares+9.3%DNAGinkgo Bioworks Holdings, Inc.$109.92Mreported value+2.58M shares+16.3%ADPTAdaptive Biotechnologies Corporation$98.96Mreported value

Reduced positions

TDOCTeladoc Health, Inc.$319.59Mreported value-148.8K shares-3.4%IONSIonis Pharmaceuticals, Inc.$223.17Mreported value-1.51M shares-17.7%VRTXVertex Pharmaceuticals Inc / Ma$181.79Mreported value-714.8K shares-48.9%FATEFate Therapeutics, Inc.$181.32Mreported value-429.7K shares

Exited positions

NSTGNanostring Technologies Inc$16.59Mprior reported value-343.5K shares-100.0%